Titan Pharmaceuticals Inc (TTNP)

[KMBJN]

Indivior's buprenorphine monthly depot injectable RBP-6000 Phase 3 results to be presented at conference:

https://finance.yahoo.com/news/indivior-plc-presents-results-phase-162400739.html

In buprenorphine treatment naive patients with OUD:

Around 40% "abstinence" (>80% of urine samples clean) vs 5% placebo

60% retention rates through 6 months vs 33% placebo

NDA submitted last month.

not sure about how it compares to Braeburn's depot / CAM2038

https://braeburnpharmaceuticals.com/braeburn-pharmaceuticals-and-camurus-announce-positive-top-line-phase-3-results-for-long-acting-buprenorphine-cam2038-for-treatment-of-opioid-addiction/

https://www.pharmaasia.com/2017/05/camurus-braeburn-pharmaceuticals-announce-positive-top-line-results-phase-3-safety-study-cam2038/

Some of these trials are vs. placebo, and some use active comparator of sublingual buprenorphine.

Will see if these depot injections get approved, if patients will prefer monthly injections or a six month implant.

I doubt we will see any head-to-head studies, certainly not of CAM2038 vs. probuphine, and would imagine CAM2038 same as Indivior's monthly depot.